# The Efficacy and Safety of Alemtuzumab in Auotoimmune Cytopenias

> **NCT00472433** · PHASE2 · TERMINATED · sponsor: **Phramongkutklao College of Medicine and Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Autoimmune Cytopenias

## Interventions

- **DRUG:** Alemtuzumab

## Key facts

- **NCT ID:** NCT00472433
- **Lead sponsor:** Phramongkutklao College of Medicine and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-03
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 30 (ESTIMATED)
- **Why stopped:** no eligible patient
- **Last updated:** 2009-06-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00472433

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00472433, "The Efficacy and Safety of Alemtuzumab in Auotoimmune Cytopenias". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00472433. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*